nach oben

Clinical Rheumatology

Erschienen in:

06.06.2020 | Review Article

Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis

verfasst von: Suling Liu, Yang Cui, Xiao Zhang

Erschienen in: Clinical Rheumatology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Iguratimod (IGU) is a novel small molecule anti-rheumatic drug with the effect of non-steroidal anti-inflammatory drug and disease-modifying anti-rheumatic drug. IGU has various mechanisms of action, including inhibition of prostaglandin E2, tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17) production, inhibition of macrophage migration inhibitory factor (MIF)-induced proinflammatory effects, inhibition of osteoclastogenesis, and promotion of osteoblastic differentiation. Ankylosing spondylitis (AS) is the major subtype of spondyloarthritis that affects the axial skeleton, causing inflammatory back pain, which can lead to impairments in structure and function and a decrease in quality of life. Theories on pathogenesis of AS include misfolding of human leukocyte antigen-B27 during its assembly leading to endoplasmic reticulum stress and unfolded protein response (UPR). Activation of UPR genes results in release of TNF-α and IL-17, which have been shown to be important in the development of AS. In addition, current evidence suggests the importance of cyclooxygenase-2/prostaglandin E2 pathway and MIF in the pathogenesis of AS. Current drugs for the treatment of AS are limited and exploration of effective drugs is needed. IGU may be effective for the treatment of AS given that its mechanisms of action are closely related to the pathogenesis of AS. In fact, several small-scale clinical trials have shown the efficacy of IGU for the treatment of AS. This article reviews the molecular mechanisms of IGU that are related to the pathogenesis of AS and clinical trials of IGU for the treatment of AS, providing a reference for future clinical application of IGU for AS.

Jiang H, Gao H, Wang Q, Wang M, Wu B (2020) Molecular mechanisms and clinical application of Iguratimod: a review. Biomed Pharmacother 122:109704PubMed

Tanaka K, Kawasaki H, Kurata K et al (1995) T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 67(4):305–314PubMed

Aikawa Y, Yamamoto M, Yamamoto T et al (2002) An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 51(4):188–194PubMed

Kohno M, Aikawa Y, Tsubouchi Y et al (2001) Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 28(12):2591–2596PubMed

Li G, Yamasaki R, Fang M et al (2018) Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Sci Rep 8(1):1933PubMedPubMedCentral

Wei Y, Sun X, Hua M et al (2015) Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int 2015:214683PubMedPubMedCentral

Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, Gu Y, Wu X, Shen Y, Xu Q (2013) A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol 191(10):4969–4978PubMed

Bloom J, Metz C, Nalawade S et al (2016) Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. J Biol Chem 291(51):26502–26514PubMedPubMedCentral

Gan K, Yang L, Xu L et al (2016) Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways. Int Immunopharmacol 35:294–300PubMed

10.

Kuriyama K, Higuchi C, Tanaka K et al (2002) A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochem Biophys Res Commun 299(5):903–909PubMed

11.

Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73–84PubMed

12.

Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390PubMed

13.

Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N (2017) Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol 13(6):359–367PubMed

14.

Pedersen SJ, Maksymowych WP (2019) The pathogenesis of ankylosing spondylitis: an update. Curr Rheumatol Rep 21(10):58PubMed

15.

Schett G, Lories RJ, D’Agostino MA et al (2017) Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13(12):731–741PubMed

16.

Ranganathan V, Ciccia F, Zeng F et al (2017) Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis Rheum 69(9):1796–1806

17.

Stojanović I, Cvjetićanin T, Lazaroski S, Stošić-Grujičić S, Miljković D (2009) Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 126(1):74–83PubMedPubMedCentral

18.

Sieper J, Poddubnyy D (2016) New evidence on the management of spondyloarthritis. Nat Rev Rheumatol 12(5):282–295PubMed

19.

Bhala N, Emberson J, Merhi A et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769–779PubMed

20.

van der Heijde D, Ramiro S, Landewe R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991PubMed

21.

Callhoff J, Sieper J, Weiß A, Zink A, Listing J (2015) Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74(6):1241–1248PubMed

22.

Boonen A, van der Heijde D, Severens JL et al (2006) Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 65(2):201–208PubMed

23.

Baeten D, Sieper J, Braun J et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548

24.

Tanaka K, Shimotori T, Makino S et al (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties. Arzneimittel-Forschung 42(7):935–944PubMed

25.

Tanaka K, Makino S, Shimotori T et al (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4′-1-benzopyran-4-o ne. 2nd communication: effect on the arachidonic acid cascades. Arzneimittel-Forschung 42(7):945–950PubMed

26.

Evans DM, Spencer CC, Pointon JJ et al (2011) Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43(8):761–767PubMedPubMedCentral

27.

Siegle I, Klein T, Backman JT et al (1998) Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 41(1):122–129PubMed

28.

Paulissen SM, van Hamburg JP, Davelaar N et al (2013) Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23. J Immunol 191(3):1364–1372PubMed

29.

Samuels JS, Holland L, Lopez M et al (2018) Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4 T-cell development during rheumatoid arthritis. Inflamm Res 67(7):589–596PubMedPubMedCentral

30.

Brenner D, Blaser H, Mak TW (2015) Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol 15(6):362–374PubMed

31.

Crew MD, Effros RB, Walford RL et al (1998) Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. J Interf Cytokine Res 18(4):219–225

32.

Redlich K, Görtz B, Hayer S et al (2004) Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum 50(3):1001–1005PubMed

33.

Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505PubMed

34.

Iwakura Y, Ishigame H, Saijo S et al (2011) Functional specialization of interleukin-17 family members. Immunity 34(2):149–162PubMed

35.

Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361(9):888–898PubMed

36.

Xu Y, Zhu Q, Song J et al (2015) Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediat Inflamm 2015:356040–356040

37.

International Genetics of Ankylosing Spondylitis C, Cortes A, Hadler J et al (2013) Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 45(7):730–738

38.

Glatigny S, Fert I, Blaton MA et al (2012) Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum 64(1):110–120PubMed

39.

Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, Kikly K, Wang R, Tseng HW, Thomas GP, Brown MA, Strutton G, McGuckin MA, Thomas R (2014) Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheum 66(7):1755–1767

40.

Mei Y, Pan F, Gao J et al (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30(2):269–273PubMed

41.

Wendling D, Cedoz J-P, Racadot E, Dumoulin G (2007) Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74(3):304–305PubMed

42.

Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13(3):R95–R95PubMedPubMedCentral

43.

Ebihara S, Date F, Dong Y, Ono M (2015) Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity 48(4):259–266PubMed

44.

Raychaudhuri SK, Saxena A, Raychaudhuri SP (2015) Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 34(6):1019–1023PubMed

45.

Gravallese EM, Schett G (2018) Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14(11):631–640PubMed

46.

Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705–1713PubMed

47.

Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3(10):791–800PubMedPubMedCentral

48.

Kozaci LD, Sari I, Alacacioglu A et al (2010) Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol 20(1):34–39PubMed

49.

Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, Matthias T, Schmidt RE, Witte T (2014) Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 73(6):1211–1214PubMed

50.

Riechers E, Baerlecken N, Baraliakos X et al (2019) Sensitivity and specificity of autoantibodies against CD74 in nonradiographic axial Spondyloarthritis. Arthritis Rheum 71(5):729–735

51.

Wang X, Ma C, Li P et al (2017) Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis. Clin Rheumatol 36(6):1369–1377PubMed

52.

Wang XT, Li P, Xu TS et al (2016) Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1β-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cell Mol Biol 62(12):44–50PubMed

53.

Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563–2574PubMed

54.

Sambrook PN, Geusens P (2012) The epidemiology of osteoporosis and fractures in ankylosing spondylitis. Ther Adv Musculoskelet Dis 4(4):287–292PubMedPubMedCentral

55.

Im CH, Kang EH, Ki JY, Shin DW, Choi HJ, Chang EJ, Lee EY, Lee YJ, Lee EB, Kim HH, Song YW (2009) Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis. Clin Exp Rheumatol 27(4):620–625PubMed

56.

Sieper J, Poddubnyy D, Miossec P (2019) The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 15(12):747–757PubMed

57.

Neerinckx B, Lories R (2017) Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis. Curr Opin Rheumatol 29(4):287–292PubMed

58.

Watad A, Bridgewood C, Russell T et al (2018) The early phases of ankylosing spondylitis: emerging insights from clinical and basic science. Front Immunol 9:2668PubMedPubMedCentral

59.

Luo Y, Zheng N, Wu R (2018) Is iguratimod effective in refractory axial spondyloarthritis? Scand J Rheumatol 47(6):518–520PubMed

60.

Qiu YY, Tang Y, Rui JB, Li J (2016) Clinical observation on treatment of refractory ankylosing spondylitis by Iguratimod. J Jiangsu Univ (Medicine Edition) 26(3):235–239

61.

Huang BJ, Ma JX (2018) Observation of short-term efficacy of iguratimod in the treatment of ankylosing spondylitis. Chin Commun Doctors 34(13):92–93

62.

Lin YP, Liu H, Gao JT (2019) Initial clinical observation on treatment of ankylosing spondylitis by Iguratimod. J Clin Rational Drug Use 12(14):9–13

63.

Xu BJ, Mo XQ, Xue XQ, Wu Y (2019) Study of the efficacy and safety of iguratimod in the treatment of ankylosing spondylitis. J New Med 50(12):915–918

64.

Zeng HQ, Kong WH, Zhuang P, Dong HJ, Yi ZH, Chen XP, Fu CZ, Ye ZH (2016) Observation of efficacy of iguratimod in the treatment of ankylosing spondylitis. Hainan Med J 27(1):118–120

Titel: Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis
verfasst von: Suling Liu
Yang Cui
Xiao Zhang
Publikationsdatum: 06.06.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 1/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05207-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

The comparison analysis of clinical and radiological features in SAPHO syndrome

Ancestral contribution of the muscle-specific creatine kinase (CKM) polymorphism rs4884 in the knee osteoarthritis risk: a preliminary study

Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study

Clinical features associated with pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes: a real-world prospective study

The basics of data, big data, and machine learning in clinical practice

Musculoskeletal ultrasound imaging training, use, and knowledge among rheumatologists in China

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin